Form 4: Atrium Therapeutics CFO Reports Stock Transaction
Insider Transaction (Form 4)
Brendan R. Winslow, Chief Financial Officer of Atrium Therapeutics, Inc., reported a transaction in 6,742 shares of common stock on September 18, 2026.
Summary
- Tax/exercise-price withholding: disposed of 6,742 Common Stock at $8.95 ($60,341) on September 18, 2026; holds 36,859 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Brendan R. Winslow — Officer (Chief Financial Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-18 | Tax/exercise-price withholding | Common Stock | 6,742 | $9 | $60.3K | 36,859 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-18 | Tax/exercise-price withholding (6,742 shares) |
Keywords
insider transaction, Form 4, RNA, Atrium Therapeutics, Inc., neutral, Brendan R. Winslow
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.